RARE vs. CRNX, PBH, BHVN, INSM, HCM, BHC, XENE, IDYA, FOLD, and JANX
Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Crinetics Pharmaceuticals (CRNX), Prestige Consumer Healthcare (PBH), Biohaven (BHVN), Insmed (INSM), HUTCHMED (HCM), Bausch Health Companies (BHC), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), Amicus Therapeutics (FOLD), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
In the previous week, Ultragenyx Pharmaceutical had 14 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 19 mentions for Ultragenyx Pharmaceutical and 5 mentions for Crinetics Pharmaceuticals. Ultragenyx Pharmaceutical's average media sentiment score of 0.95 beat Crinetics Pharmaceuticals' score of -0.15 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.
Crinetics Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 7.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 6.8% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Crinetics Pharmaceuticals currently has a consensus price target of $54.00, indicating a potential upside of 14.41%. Ultragenyx Pharmaceutical has a consensus price target of $88.00, indicating a potential upside of 105.85%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Ultragenyx Pharmaceutical has a net margin of -138.58% compared to Ultragenyx Pharmaceutical's net margin of -4,223.27%. Ultragenyx Pharmaceutical's return on equity of -52.93% beat Crinetics Pharmaceuticals' return on equity.
Ultragenyx Pharmaceutical received 669 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. Likewise, 77.09% of users gave Ultragenyx Pharmaceutical an outperform vote while only 66.18% of users gave Crinetics Pharmaceuticals an outperform vote.
Summary
Ultragenyx Pharmaceutical beats Crinetics Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultragenyx Pharmaceutical Competitors List
Related Companies and Tools
